My Personal Therapeutics

My Personal Therapeutics (MPT) is revolutionizing cancer treatment with its Personalised Cancer Drug recommendation. Developed at the Center for Personalized Cancer Therapeutics (CPCT) at the Icahn School of Medicine at Mount Sinai, the Personal Discovery Process (PDP) involves whole exome sequencing of tumor and non-tumor tissue, unbiased identification of potential tumorigenic mutations, and the incorporation of these mutations into fruit flies to serve as patient avatars. This is followed by massive screening campaigns of all FDA-approved drugs to identify specific drug combinations for individual patients, with over 400K fruit flies involved in the process. Through the use of robotics, more than 1,200 FDA-approved drugs, including non-cancer drugs, are evaluated to identify combinations that significantly improve mortality in the avatar population. Ultimately, the drug combinations are presented to a tumor board to make the best treatment recommendation for the patient. MPT's PDP represents the most comprehensive drug screening service for individuals with cancer. Founded in 2018 and based in the United Kingdom, MPT presents a compelling opportunity for investors in the health care industry.